2020
Karo Pharma AB divests its Hospital Supply business, Swereco AB, to J2L Holding AB
As previously announced, Karo Pharma AB (“Karo Pharma”) has carried out a strategic evaluation of the Hospital Supply business unit,…
Karo Pharma publishes third-quarter report 2020 and resolves on sale of own shares
Q3, July – September Net sales amounted to MSEK 679.1 (443.7). This corresponds to an increase of 53% for the…
Second-quarter report 2020
Q2, April – June Net sales amounted to MSEK 688.9 (387.4). This corresponds to an increase of 78% for the…
Annual general meeting 2020 in Karo Pharma Aktiebolag
At today’s annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt…
Karo Pharma acquires Pevaryl® brand portfolio from Cilag GmbH International, an affiliate of Johnson & Johnson
Karo Pharma Aktiebolag (“Karo Pharma”) today announces the signing and closing of the acquisition of the remaining European rights to…
Interim report Q1 2020
January – March Net sales amounted to MSEK 793.6 (420.8). This corresponds to an increase of 89% for the period.…
Karo Pharma enters the Swiss market with direct presence by acquiring Hygis SA
Karo Pharma AB (Karo) has today acquired Hygis SA (Hygis), a Swiss distributing company with exclusive distribution rights to Karo’s…
Karo Pharma publishes the 2019 annual report
Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company’s website, www.karohealthcare.com. FOR…
Karo Pharma postpones the Annual General Meeting to 25 May, 2020
The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the Annual General Meeting to 25…